该项收购完成后,Cambrex公司将获得Avista公司包括从原料药、药品开发、环化核苷酸制造,到独立分析、微生物测验以及固态科学等多项服务,同时将Avista的4个制药站点纳入其生...查看全文
琬麟2015-02-07 09:21
$凯姆布雷克斯(CBM)$ EAST RUTHERFORD, N.J., Feb. 6, 2015 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to announce that it has initiated the second significant expansion of its Charles City, Iowa facility in less than three years. Strong continu...查看全文
$凯姆布雷克斯(CBM)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2019-10-31 AccNo: 0001564590-19-039033 Size: 11 MB 网页链接
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2019-10-24 AccNo: 0001193125-19-273038 Size: 208 KBItem 2.02: Results of Operations and Financial ConditionItem 5.07: Submission of Matters to a Vote of Security HoldersItem 9.01: Financial Statements and Exhibits 网页链接
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2019-10-17 AccNo: 0001193125-19-269386 Size: 157 KBItem 8.01: Other Events 网页链接
$凯姆布雷克斯(CBM)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-10-17 AccNo: 0001193125-19-269395 Size: 26 KB 网页链接
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2019-10-15 AccNo: 0001193125-19-267758 Size: 247 KBItem 8.01: Other Events 网页链接
$凯姆布雷克斯(CBM)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-10-15 AccNo: 0001193125-19-267764 Size: 80 KB 网页链接
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2019-09-23 AccNo: 0001193125-19-252190 Size: 165 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$凯姆布雷克斯(CBM)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-09-23 AccNo: 0001193125-19-252193 Size: 32 KB 网页链接
$凯姆布雷克斯(CBM)$ DEFM14A - Definitive proxy statement relating to merger or acquisition Filed: 2019-09-23 AccNo: 0001193125-19-252275 Size: 1 MB 网页链接
$凯姆布雷克斯(CBM)$ PREM14A - Preliminary proxy statements relating to merger or acquisition Filed: 2019-09-06 AccNo: 0001193125-19-239145 Size: 1 MB 网页链接